EULAR 2022

Updated EULAR RA recommendations: does it change the status of JAKies?

Prevention of RA possible by treating very early?

The road of glucocorticoids in RA

Rapid tapering of steroids - how quickly should we taper the patient?

HOT - Difficulties in treatment of RA

Double-blind placebo controlled trial of MTX in patients with arthralgia at risk for RA

Analysis of baseline ORAL surveillance data: is it due to patient history and geography?

Radiographic progression in RA patients in daily practice is independent of stringent T2T strategy

Risk of venous thromboembolic events in ORAL Surveillance study

Can early abatacept therapy in high-risk patients prevent onset of RA?

The significance of depression and air pollution in patients with RA

Does MTX have a disease modifying effect in patients with arthralgia?

Interest of methotrexate before the emergence of RA

Metotrexate en pacientes con artralgia inflamatoria en riesgo de evolución a artritis reumatoide un ensayo​Dear Sara doble ciego

Liegt es an Vorgeschichte und oder Geographie?

Radiologische Progression ist unabhängig von stringenter T2T-Strategie

Riesgo de eventos tromboembolicos en el ORAL Surveillance

MRT auch ohne Kontrastmittel bei RA einsetzbar

Frühzeitige Abatacept-Therapie bei Hochrisiko RA präventiv?

Abordaje de la artritis reumatoide difícil de tratar

Betydning av depresjon og luftforurensning hos pasienter med revmatiske sykdommer

Har MTX en sykdomsmodifiserende effekt hos pasienter med leddsmerter og subklinisk leddinflammasjon?

Interet du méthotrexate avant l´émergence de la PR

New data on IL-17 inhibition and a 1st in class molecule

The (unmet) need for perspective biomarkers in SpA

Hot topic spine: axial diseases in SpA and suitable activity scores

A new treatment for PsA

Low rates of sustained remission in a real world setting in PsA patients

PsA is associated with a higher risk of hematological malignancies

Every joint counts! Even patients with LJC should be treated to target

Guselkumab "more safe" than Placebo

Who has the best chance of being in prolonged remission in psoriasis arthritis?

First in class: new molecule to inhibit IL-17A

Course of ultrasound-detected synovitis in PsA patients receiving secukinumab

Revival of leflunomide - the combination with MTX

New therapies for PsA

Guselkumab "sicherer" als Plazebo

Novità nel trattamento dell’Artrite Psoriasica

PsA mit einem höheren Risiko für hämatologische Malignitäten assoziiert?

Neues Molekül zur Hemmung von IL-17A

Qui a le plus de chance d´etre en rémission prolongee dans le rhumatisme psoriasique?

Geringe Raten an anhaltender Remission im Real Wold Setting

Verlauf von sonographischer Synovitis unter Secukinumab

Revival von Leflunomid - in Kombination mit MTX

Jedes Gelenk zählt! Auch bei niedrigem Joint Count Treat-to-Target

New ASAS/EULAR axSpA recommendations

Artificial intelligence in axSpA

A deep dive review of axSpA

New drugs in axSpA

Rates of progression from non-radiographic to radiographic axSpA

Percentuale di progressione da forma non radiografica a radiografica di AxSpA

Nuevos terapias en EspAax

Rivisitazione dell’impegno assiale dell'artrite psoriasica

Nuevos recomendaciones ASAS/EULAR en EspAax

Inteligencia artificial en EspAax

Voclosporin for Lupus Nephritis

Deucravacitinib for Lupus Erythematosus - Phase II study

TYK2-Inhibitor Deucravacitinib wirksam und verträglich

Voclosporin bei Lupus Nephritis

Vaccination response against COVID-19 in patients with immune-mediated inflammatory diseases

Type of mRNA COVID-19 vaccine influences antibody kinetics

Predictive severity factors of COVID-19 in R-IMID patients

Vaccination in rheumatic diseases including COVID-19

Antikörperkinetik unter verschiedenen mRNA-COVID-19-Impfstoffen

Vaksine respons (COVID-19) hos pasienter med immunmedierte inflammatoriske sykdommer

GM-CSF is increased in patients with AS and persists despite anti-TNF treatment

I livelli di GM-CSF sono incrementati nei pazienti con AS e non modulati dal trattamento con anti-TNF

The microbiota to predict the response to the treatment of psoriasis arthritis

New developments in the field of osteoarthristis

Link between biomechanical stretch and synovial inflammation

Real-world data of an etanercept biosimilar (GP2015) in rheumatic diseases

Management of calcific tendonitis by BARBOTAGE

Pain - challenges in clinical practice

Legame tra stress biomeccanico e infiammazione sinoviale

Le microbiote pour prédire la réponse au traitement du rhumatisme psoriasique